A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?

Détails

ID Serval
serval:BIB_5082D60AB0F2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Périodique
Lung Cancer
Auteur(s)
Demierre N., Zoete V., Michielin O., Stauffer E., Zimmermann D.R., Betticher D.C., Peters S.
ISSN
1872-8332 (Electronic)
ISSN-L
0169-5002
Statut éditorial
Publié
Date de publication
2013
Volume
80
Numéro
1
Pages
81-84
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish. PDF type: Case report
Résumé
We report on the medical history of a Caucasian smoker woman diagnosed with a stage IV NSCLC adenocarcinoma, characterized by a rare epidermal growth factor receptor (EGFR) point mutation in exon 21 codon 843 (p.V843I/c.2527G>A/COSMIC ID 85894). This genetic alteration revealed to be germline, after its presence was demonstrated in chondroblasts from the bone biopsy. While it is the first description of germline V843I mutation without concomitant additional known EGFR activating mutation, we modeled the EGFR ATP catalytic domain in complex with ATP, gefitinib and erlotinib using computer-aided approaches to estimate possible changes in affinity upon the V843I mutation.
Pubmed
Web of science
Création de la notice
21/04/2013 9:32
Dernière modification de la notice
03/03/2018 17:09
Données d'usage